ArticleInternational journal of biological sciences2024
UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT.
Article in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation.Signal transduction and targeted therapy · 2026Review
- UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.Current issues in molecular biology · 2026Review
- Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis.Cell death discovery · 2026Article
- MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy.Functional & integrative genomics · 2026Article
- Integrated multi-technology exploration of the mechanism by which Badushengji San regulates core targets in diabetic foot ulcer.Molecular genetics and genomics : MGG · 2026Article
- Bisphenol S drives breast cancer metastasis by inhibiting dopamine receptor D2 to activate the Akt/GSK3β oncogenic axis.Journal of advanced research · 2026Article
- Therapeutic strategies for MMAE-resistant bladder cancer through DPP4 inhibition.Molecular oncology · 2026Article
- Post-translational modifications: Principal regulators of bladder cancer.Molecular biology reports · 2026Review
- Medicarpin reduces cisplatin resistance and causes apoptosis by inhibiting the AKT/Bcl2 pathway in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Integrated single-cell and spatial transcriptomics reveal the differentiation drivers of gastric epithelial lineage progression.Frontiers in immunology · 2026Article
- Construction of a gene-metabolite-microbiome regulatory network reveals novel therapeutic targets in bladder cancer through multi-omics analysis.Annals of medicine · 2025Article
- Research progress on the role of AGC kinase family in bladder cancer.Discover oncology · 2025Review
- UPP1 is a dual biomarker of prognosis and immune microenvironment in IDH wild-type glioblastoma.Scientific reports · 2025Article
- Uridine as a hub in cancer metabolism and RNA biology.Experimental & molecular medicine · 2025Review
- Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of emerging therapeutic targets.iScience · 2025Review
- UPP1 and AHSA1 as emerging biomarkers and targets in pancreatic cancer: A proteomic approach.Biomolecules & biomedicine · 2025Article
- Predicting survival and immune status of breast cancer patients based on prognostic features related to PANoptosis.Discover oncology · 2025Article
- DDX49 as a novel prognostic biomarker regulates colorectal cancer cell proliferation through the TIMM44-PI3K-AKT pathway.Frontiers in oncology · 2025Article
- The causal relationship between CSF metabolites and GBM: a two-sample mendelian randomization analysis.BMC cancer · 2024Article
- Single-cell sequencing of facial adipose tissue unveils FKBP5 as a therapeutic target for facial infiltrating lipomatosis.Stem cell research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
UPP1, a crucial pyrimidine metabolism-related enzyme, catalyzes the reversible phosphorylation of uridine to uracil and ribose-1-phosphate. However, the effects of UPP1 in bladder cancer (BLCA) have not been elucidated. AKT, which is activated mainly through dual phosphorylation (Thr308 and Ser473), promotes tumorigenesis by phosphorylating downstream substrates. This study demonstrated that UPP1 promotes BLCA cell proliferation, migration, invasion, and gemcitabine resistance by activating the AKT signaling pathway
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.